人类癌症中SMAD4非终止突变导致功能丧失
该研究回顾性分析38002例肿瘤标本的测序数据,评估SMAD4突变谱,发现4例SMAD4非终止突变(2例胰腺腺癌、1例结肠腺癌、1例非小细胞肺癌),免疫组化显示这4例肿瘤均丢失SMAD4蛋白表达,提示非终止突变应临床解读为致病性功能丧失变异。
要点
- SMAD4非终止突变在多种肿瘤中导致SMAD4蛋白表达丢失。
- 临床测序发现SMAD4非终止突变应解读为致病性功能丧失。
- SMAD4突变最常见于胃肠道肿瘤。
核心结论
- SMAD4非终止突变在多种肿瘤类型中与SMAD4蛋白表达丢失相关。
- 在癌症测序 panel 中发现 SMAD4 非终止突变时,应临床解读为致病性功能丧失变异。
研究设计与样本
- 回顾性分析38002例肿瘤标本的癌症测序数据库,评估SMAD4突变谱。
- 对携带SMAD4非终止突变的肿瘤进行免疫组化评估SMAD4蛋白表达。
主要发现
- 在1822例肿瘤中鉴定出1956个SMAD4突变。
- SMAD4突变最常见于胃肠道肿瘤,包括无义变异(n=344)、移码插入缺失(n=258)、剪接位点变异(n=104)和R361密码子错义变异(n=245)。
- 在免疫组化子集中,蛋白截短变异肿瘤中23/25(92%)丢失SMAD4表达,错义变异肿瘤中7/27(26%)丢失表达。
- 4例携带SMAD4非终止突变:2例胰腺腺癌、1例结肠腺癌、1例非小细胞肺癌。
- 免疫组化显示所有4例SMAD4非终止突变肿瘤均丢失SMAD4蛋白表达。
关键数值与推荐
- 蛋白截短变异肿瘤中SMAD4表达丢失率为23/25(92%)。
- 错义变异肿瘤中SMAD4表达丢失率为7/27(26%)。
- SMAD4非终止突变在4例肿瘤中鉴定(2例胰腺腺癌、1例结肠腺癌、1例非小细胞肺癌)。
临床怎么用
- 在癌症测序 panel 中检出 SMAD4 非终止突变时,应将其解读为致病性功能丧失变异。
- 可结合免疫组化检测 SMAD4 蛋白表达丢失来辅助解读非终止突变的致病性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: SMAD4 is a tumour suppressor gene that is mutated in a variety of cancers. SMAD4 nonstop mutations, which convert stop codons to sense codons that extend transcription, have been identified in genomic databases but have not been characterised in human pathology samples. The frequency of SMAD4 nonstop mutations and the consequences of nonstop mutations on SMAD4 protein expression are unknown. METHODS: We retrospectively analysed our cancer sequencing database of 38,002 tumour specimens and evaluated the spectrum of SMAD4 mutations. SMAD4 protein expression was evaluated by immunohistochemistry in tumours with SMAD4 nonstop mutations. RESULTS: In total, 1956 SMAD4 mutations were identified in 1822 tumours. SMAD4 mutations were most common in tumours of the gastrointestinal tract and included nonsense variants (n = 344), frameshift indels (n = 258), splice site variants (n = 104), and missense variants at codon R361 (n = 245). In a subset of cases with immunohistochemistry, SMAD4 expression was lost in 23 of 25 tumours (92%) with protein truncating variants and in 7 of 27 tumours (26%) with missense variants. Four cases harboured SMAD4 nonstop mutations. SMAD4 nonstop mutations were identified in two pancreatic adenocarcinomas, one colonic adenocarcinoma, and one non-small cell lung carcinoma. Immunohistochemistry demonstrated loss of SMAD4 protein expression in each of the four tumours with SMAD4 nonstop mutations. CONCLUSION: SMAD4 nonstop mutations are associated with loss of SMAD4 protein expression in multiple tumour types. SMAD4 nonstop mutations should be clinically interpreted as pathogenic loss of function alterations when identified in cancer sequencing panels.
引用
- Bauer AH, Basta DW, Hornick JL, et al. Loss of function SMAD4 nonstop mutations in human cancer. Histopathology. 2023. PMID: 36740808. doi:10.1111/his.14880
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。